UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006163 |
|---|---|
| Receipt number | R000007284 |
| Scientific Title | Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancer |
| Date of disclosure of the study information | 2011/08/12 |
| Last modified on | 2022/08/20 11:00:38 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancer
Acronym
Chemotherapy with gemcitabine and nafamostat mesilate for the patients with resectable pancreatic cancer
Scientific Title
Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancer
Scientific Title:Acronym
Chemotherapy with gemcitabine and nafamostat mesilate for the patients with resectable pancreatic cancer
Region
| Japan |
Condition
Condition
Adenocarcinoma of pancreas after curative resection
Classification by specialty
| Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy of adjuvant chemotherapy with gemcitabine and nafamostat mesilate for the patients with resectable adenocarcinoma of pancreas.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Overall Survival
Key secondary outcomes
Disease Free survival
one-year and three-year survival rate
incidence rate of adverse events
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Gemcitabine was i.v. administered at a fixed dose of 1000 mg/m2 for 30 min on days 1, 8 and 15, every 4 weeks for six cycles.
Nafamostat mesilate is administered via a port-catheter system for 24 h through the common hepatic artery and celiac artery on days 1, 8 and 15, every 4 weeks for six cycles.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)Patients of age =>20 and 80>
2)Patients with gross complete (R0 or R1) resection of adenocarcinoma of pancreas
3)Tolerable to chemotherapy within 8 weeks after surgery
4)Karnofsky performance status =>70%
5)Hemoglobin >=9.0g/dl,
WBC>=3,000/mm3,12,000/mm3,
Neutrophils >=1,500/mm3,
Platelets >=100,000/mm3,
AST/ALT </=2.5 x ULN,
Total bilirubin </=2.0 x ULN,
Serum creatinine </=1.0 x ULN,
BUN </=1.0 x ULN,
PaO2 >= 70 torr
Creatinine clearance>=60 ml/min
6)No replaced common hepatic artery, gastroduodenal artery and celiac artery
7)Written informed consent
Key exclusion criteria
1)Pulmonary fibrosis or interstitial pneumonia detectable on chest X-ray
2)Active infection
3)Uncontrollable heart disease and myocardial infarction within 6 months
4)Uncontrollable DM
5)Pregnant or lactation women, or women with known or suspected pregnancy
6)History of severe drug allergy
7)Active synchronous or metachronous malignancy
8)Severe complications after operation
9)No chemotherapy or radiotherapy for pancreatic cancer in the past
10)Patients who are judged inappropriate for the entry into the study by the investigater
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Katsuhiko Yanaga |
Organization
Jikei University school of Medicine
Division name
Department of surgery, Division of hepatobiliary pancreas surgery
Zip code
Address
3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tadashi Uwagawa |
Organization
Jikei University school of Medicine
Division name
Department of surgery, Division of hepatobiliary pancreas surgery
Zip code
Address
TEL
Homepage URL
uwatadashi@msn.com
Sponsor or person
Institute
Jikei University school of Medicine
Institute
Department
Personal name
Funding Source
Organization
Jikei University school of Medicine
Department of surgery
Division of hepatobiliary pancreas surgery
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 08 | Month | 12 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 07 | Month | 04 | Day |
Date of IRB
| 2011 | Year | 07 | Month | 04 | Day |
Anticipated trial start date
| 2011 | Year | 08 | Month | 01 | Day |
Last follow-up date
| 2021 | Year | 01 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 08 | Month | 12 | Day |
Last modified on
| 2022 | Year | 08 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007284
